Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 7/20 | 0.58 |
| ▸ | DDR1 | Q08345 | 7/20 | 0.58 |
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689713 | 0.89 | DDR2 (0.60) | DDR2DDR1KITMAPK14LCK | |
| SCHEMBL17208652 | 0.83 | PIKFYVE (0.56) | DDR2DDR1KITLCKCSF1R | |
| SCHEMBL14704634 | 0.79 | DDR1 (0.81) | DDR1MAPK14SRCATMEPHB2 | |
| SCHEMBL22457384 | 0.78 | MAPK14 (0.61) | KITMAPK14LCKSRCCSF1R | |
| SCHEMBL17208706 | 0.77 | DDR1 (0.55) | DDR2DDR1MAPK14POLBMAPT | |
| SCHEMBL12518523 | 0.77 | LCK (0.64) | DDR2DDR1KITMAPK14LCK | |
| SCHEMBL12517071 | 0.77 | DDR2 (0.62) | DDR2DDR1KITMAPK14LCK | |
| SCHEMBL13708164 | 0.76 | LCK (0.58) | KITMAPK14LCKSRCCSF1R | |
| SCHEMBL17208620 | 0.76 | DDR1 (0.55) | DDR1MAPK14MAPTHTT | |
| SCHEMBL17208707 | 0.75 | MAPT (0.47) | DDR2DDR1LCKPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | DDR2 922/4885DDR1 1181/4885KIT 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.